Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2005-2006 flu vaccine

Executive Summary

GlaxoSmithKline plans to provide up to 10 mil. doses of Fluarix influenza vaccine for the upcoming season. GSK says it has started the manufacturing ramp up and the Fluarix BLA will be submitted in mid '05, possibly as early as late May...

You may also be interested in...

Fluarix BLA filed

GlaxoSmithKline announced May 25 the submission of a BLA for its influenza agent Fluarix. In early May, GSK said it plans to provide 10 mil. doses of the product for the 2005-06 flu season and that it had already started the manufacturing ramp-up (1"The Pink Sheet" May 9, 2005, In Brief)...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts